Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists

Circulation

Volumn 98, Issue 16, 1998, Pages 1616-1621

  Storey, R F ^a   Wilcox, R G ^a   Heptinstall, S ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Calcium; Glycoproteins; Platelet aggregation inhibitors

Indexed keywords

4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; MK 0852; REVASE; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; TURBIDIMETRY;

EID: 0032552978     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.16.1616     Document Type: Article

References (29)

1. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ, for the EPIC Investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;77:1045-1051.
2. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.
3. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation. 1997;96: 1117-1121.
4. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson V, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. Effects of Integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation. 1996;94:2083-2089.
5. Simoons ML, Jan de Boer M, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wicken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994; 89:596-603.
6. Ohman E, Kleiman N, Gacioch G, Worley S, Navetta F, Talley J, Anderson V, Ellis S, Cohen M, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt M, Sigmon K, Califf R, Krucoff M, Topol E. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Circulation. 1997;95:846-854.
7. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation. 1995;91: 2151-2157.
8. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault J-R, Detage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban study. Circulation. 1996;94:899-905.
9. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
10. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
11. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff M, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76: 1222-1227.
12. Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab: administration for complex coronary intervention. Circulation. 1996;94:906-910.
13. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-1671.
14. Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ. First chronic platelet glycoprotein IIb/IIIa integrin blockade: a randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation. 1997;96:76-81.
15. 2+ on GP IIb-IIIa interactions with Integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
16. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation. 1997;95: 860-867.
17. Fox S, Burgess-Wilson M, Heptinstall S, Mitchell J. Platelet aggregation in whole blood determined using the Ultra-Flo 100 platelet counter. Thromb Haemost. 1982;48:327-329.
18. Thompson N, Scrutton M, Wallis R. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb Res. 1986; 41:615-626.
19. Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD, Chang CT, Nutt RF, Brady SF, Veber DF, Anderson PS, Shebuski RJ, Friedman PA, Gould RJ. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis. J Pharmacol Exp Ther. 1993;266: 1501-1511.
20. Foster M, Pike N, Hornby E, Porter B, Eldred C, Ross B, Lumley P. GR144053, a potent and specific non-peptide fibrinogen receptor antagonist on human platelets in vitro. Thromb Haemost. 1993;69:559.
21. Bevan J, Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res. 1985; 38:189-194.
22. Frojmovic M, Mooney R, Wong T. Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding II: quantal activation parallels platelet capture in stir-associated microaggregation. Biophys J. 1994;67:2069-2075.
23. Legrand C, Dubernard V, Rabhi-Sabile S, Morandi da Silva V. Functional and clinical significance of thrombospondin. Platelets. 1997;8:211-223.
24. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
25. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with epifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Eng J Med. 1998;339:436-443.
26. Gralnick H, Williams S, McKeown L, Connaghan G, Shafer B, Hansmann K, Vail M, Fenton J. Endogenous platelet fibrinogen surface expression on activated platelets. J Lab Clin Med. 1991;118:604-613.
27. Legrand C, Dubernard V, Nurden A. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood. 1989;73:1226-1234.
28. Armstrong R, May JA, Losche W, Heptinstall S. Factors that contribute to spontaneous platelet aggregation and streptokinase-induced aggregation in whole blood. Thromb Haemost. 1995;73:297-303.
29. Packham M, Kinlough-Rathbone R, Mustard J. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation upon close contact of human platelets in media with a low concentration of ionized calcium. Blood. 1987;70:647-651.